Show simple item record

dc.contributor.authorYuan, Xun
dc.contributor.authorZheng, Zhiqin
dc.contributor.authorLiu, Fangfang
dc.contributor.authorGao, Yuan
dc.contributor.authorZhang, Wenhui
dc.contributor.authorBerardi, Rossana
dc.contributor.authorMohindra, Pranshu
dc.contributor.authorZhu, Zhengfei
dc.contributor.authorLin, Jie
dc.contributor.authorChu, Qian
dc.date.accessioned2021-06-07T15:46:15Z
dc.date.available2021-06-07T15:46:15Z
dc.date.issued2021-05-01
dc.identifier.urihttp://hdl.handle.net/10713/15932
dc.description.abstractBackground: Small cell lung cancer (SCLC) makes up 13% of lung malignancies. Only one-third of SCLC patients received their diagnosis at the limited stage. Treatment for symptomatic extensive-stage (ES) SCLC with persistent intrathoracic disease is still controversial. The present research aimed to analyze the impact of palliative thoracic radiotherapy (TRT) as a treatment for this patient group and build a prognostic nomogram. Methods: In this retrospective, multi-center study, we analyzed 120 patients with ES-SCLC and a World Health Organization performance status of 1–2 who were diagnosed between March 2014 and September 2019. A nomogram was formulated to predict the patients’ 1- and 2-year overall survival (OS). Results: The study cohort had a median age of 62 years, and males accounted for 85% of enrollees. A significant extension was observed in the median OS in the TRT group compared to the no TRT group (P<0.001). When the patients were stratified by TRT dose, no significant differences in OS were noted (P=0.530). However, higher levels of inflammatory markers prior to TRT were associated with a shorter OS (neutrophil-to-lymphocyte ratio, P=0.002; platelet/lymphocyte ratio, P=0.023). The nomogram’s Harrell’s concordance (C)-statistic reached 0.70, and the calibration curve analysis revealed goodness of fit. Conclusions: The neutrophil-to-lymphocyte ratio is an independent factor predicting survival in ES-SCLC patients treated with palliative TRT. Our nomogram, which incorporates immunological markers, has higher accuracy than existing models for the prediction of individuals’ chances of survival, and it could be a significant tool for clinicians in the development of tailored therapeutic strategies.en_US
dc.description.sponsorshipNational Natural Science Foundation of Chinaen_US
dc.description.urihttps://doi.org/10.21037/tlcr-21-211en_US
dc.language.isoenen_US
dc.publisherSociety for Translational Medicine (STM)en_US
dc.relation.ispartofTranslational Lung Cancer Researchen_US
dc.subjectExtensive stage small cell lung cancer (ES-SCLC)en_US
dc.subjectNeutrophil-to-lymphocyte ratio (NLR)en_US
dc.subjectNomogramen_US
dc.subjectPalliative thoracic radiotherapy (TRT)en_US
dc.subjectPlatelet/lymphocyte ratio (PLR)en_US
dc.titleA nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapyen_US
dc.typeArticleen_US
dc.identifier.doi10.21037/tlcr-21-211
dc.source.volume10
dc.source.issue5
dc.source.beginpage2163
dc.source.endpage2171


This item appears in the following Collection(s)

Show simple item record